Sethi Atin, Bach Horacio
Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Department of Medicine, Division of Infectious Diseases, University of British Columbia, Vancouver, BC ADD ED8, Canada.
Microorganisms. 2020 Jul 22;8(8):1097. doi: 10.3390/microorganisms8081097.
The virus SARS-CoV-2, the etiological agent of COVID-19, is responsible for more than 400,000 deaths worldwide as of 10 June 2020. As a result of its recent appearance (December 2019), an efficacious treatment is not yet available. Although considered a lung infection since its emergence, COVID-19 is now causing multiple organ failure, requiring a continuous adjustment in the procedures. In this review, we summarize the current literature surrounding unproven therapies for COVID-19. Analyses of the clinical trials were grouped as chemotherapy, serotherapy, anticoagulant, and the use of human recombinant soluble ACE2 therapies. We conclude that, while no agent has hit the threshold for quality of evidence to demonstrate efficacy and safety, preliminary data show potential benefits. Moreover, there is a possibility for harm with these unproven therapies, and the decision to treat should be based on a comprehensive risk-benefit analysis.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是冠状病毒病（COVID-19）的病原体，截至2020年6月10日，已在全球造成超过40万人死亡。由于它最近才出现（2019年12月），目前尚无有效的治疗方法。尽管自出现以来一直被认为是肺部感染，但COVID-19目前正在导致多器官功能衰竭，这就需要对治疗程序不断进行调整。在本综述中，我们总结了目前有关COVID-19未经证实疗法的文献。对临床试验的分析分为化疗、血清疗法、抗凝疗法以及使用人重组可溶性血管紧张素转换酶2（ACE2）疗法。我们得出的结论是，虽然尚无任何药物达到证明疗效和安全性的证据质量门槛，但初步数据显示出潜在益处。此外，这些未经证实的疗法有可能造成伤害，治疗决策应基于全面的风险效益分析。
